{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:05:26Z","timestamp":1789056326894,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Studies diverge on the relevance of long-term protection of anti-VEGF against severe proliferative diabetic retinopathy (PDR) complications compared to pan-retinal photocoagulation (PRP). We aim to assess this dispute through a meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched PubMed, Embase, and Cochrane databases until August 2024 for studies comparing anti-VEGF with PRP in PDR. Primary outcomes were long-term and short-term incidences of VH, TRD, and PPV\u2014setting short-term follow-up up to 2 years and long-term follow-up over 5 years. Due to a lack of consistent data, TRD events were not stratified by clinical severity. We also evaluated diabetic macular edema (DME) rates and changes in best corrected visual acuity (BCVA) and central macular thickness (CMT). We used R to pool risk ratios (RR) and weighted mean differences with a random-effects model, and appraised evidence certainty using the GRADE tool. PROSPERO CRD42024577668.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We included eight studies with 12,812 eyes. Long-term data showed anti-VEGF reducing TRD (3.4% vs. 11.5%; RR 0.31, 95% CI 0.23\u20130.42; <jats:italic>p<\/jats:italic>\u2009=\u20090.001) with high certainty of evidence. However, PPV (7.8% vs. 9.4%; <jats:italic>p<\/jats:italic>\u2009=\u20090.116) and VH rates (11% vs. 18%; <jats:italic>p<\/jats:italic>\u2009=\u20090.38) did not differ, with moderate and low evidence certainty, respectively. In the short term, anti-VEGF demonstrated superiority in BCVA and CMT outcomes and reduced DME rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although anti-VEGF was associated with lower TRD rates in the long term, the absence of severity data and the lack of differences in PPV and VH raise questions about its clinical relevance. Long-term findings are limited to only two studies. Future research should stratify TRD by severity and include extended follow-up. In contrast, short-term outcomes consistently favored anti-VEGF for both visual and anatomical results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00687-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:44:19Z","timestamp":1752137059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Meta-analysis: long\/short-term efficacy of anti-VEGF vs. panretinal photocoagulation in preventing severe complications in proliferative diabetic retinopathy"],"prefix":"10.1186","volume":"11","author":[{"given":"Tiago N. O.","family":"Rassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas M.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillan Cunha","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo N.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helv\u00e9cio N. F.","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme N.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno C.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"687_CR1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"Early photocoagulation for diabetic retinopathy","year":"1991","unstructured":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology. 1991;98:766\u201385.","journal-title":"Ophthalmology"},{"key":"687_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA. 2015;314:2137\u201346.","journal-title":"JAMA"},{"key":"687_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"S Sivaprasad","year":"2017","unstructured":"Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal Aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193\u2013203.","journal-title":"Lancet"},{"key":"687_CR4","doi-asserted-by":"crossref","unstructured":"Alsoudi AF, Wai KM, Koo E et al. Progression to Pars plana vitrectomy in patients with proliferative diabetic retinopathy. JAMA Ophthalmol. 2024.","DOI":"10.1001\/jamaophthalmol.2024.1844"},{"key":"687_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross JG, Glassman AR, Liu D, et al. Five-Year outcomes of panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol. 2018;136:1138\u201348.","journal-title":"JAMA Ophthalmol"},{"key":"687_CR6","unstructured":"Higgins JPTTJ. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). 2023."},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"687_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","volume":"6","author":"TA Ciulla","year":"2022","unstructured":"Ciulla TA, Hussain RM, Taraborelli D, et al. Longer-Term Anti-VEGF therapy outcomes in neovascular Age-Related macular degeneration, diabetic macular edema, and vein Occlusion-Related macular edema: clinical outcomes in 130 247 eyes. Ophthalmol Retina. 2022;6:796\u2013806.","journal-title":"Ophthalmol Retina"},{"key":"687_CR9","doi-asserted-by":"crossref","unstructured":"Butkut\u0117 E, Zieni\u016bt\u0117 M, Mork\u016bnait\u0117 A, Bal\u010di\u016bnien\u0117 VJ. Short-Term and Long-Term effects of bariatric surgery on diabetic retinopathy: A systematic review. Med Kaunas Lith. 2025;61.","DOI":"10.3390\/medicina61010157"},{"key":"687_CR10","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2337\/dc09-0565","volume":"32","author":"R Sim\u00f3","year":"2009","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556\u201362.","journal-title":"Diabetes Care"},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"687_CR12","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"687_CR13","doi-asserted-by":"crossref","unstructured":"Schwarzer G. An R Package for Meta-Analysis. 2007.","DOI":"10.32614\/CRAN.package.meta"},{"key":"687_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0145445516673998","volume":"41","author":"D Drevon","year":"2017","unstructured":"Drevon D, Fursa SR, Malcolm AL. Intercoder reliability and validity of webplotdigitizer in extracting graphed data. Behav Modif. 2017;41:323\u201339.","journal-title":"Behav Modif"},{"key":"687_CR15","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1111\/j.1755-3768.2011.02364.x","volume":"90","author":"BJ Ernst","year":"2012","unstructured":"Ernst BJ, Garc\u00eda-Aguirre G, Oliver SCN, et al. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-na\u00efve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol (Copenh). 2012;90:e573\u2013574.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"687_CR16","first-page":"34","volume":"235","author":"J Figueira","year":"2016","unstructured":"Figueira J, Silva R, Henriques J, et al. Ranibizumab for High-Risk proliferative diabetic retinopathy: an exploratory randomized controlled trial. Ophthalmol J Int Ophtalmol Int J Ophthalmol. 2016;235:34\u201341.","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol"},{"key":"687_CR17","doi-asserted-by":"crossref","unstructured":"Marashi AAI. Panretinal photocoagulation versus intravitreal bevacizumab for proliferative diabetic retinopathy treatment. Adv Ophthalmol Vis Syst. 2017.","DOI":"10.15406\/aovs.2017.07.00211"},{"key":"687_CR18","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1111\/aos.14312","volume":"98","author":"GE Lang","year":"2020","unstructured":"Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of Ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy\u2013 the PRIDE study. Acta Ophthalmol (Copenh). 2020;98:e530\u20139.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"687_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/IAE.0000000000003450","volume":"42","author":"T Shahraki","year":"2022","unstructured":"Shahraki T, Arabi A, Nourinia R, PANRETINAL PHOTOCOAGULATION VERSUS INTRAVITREAL BEVACIZUMAB VERSUS A PROPOSED MODIFIED COMBINATION THERAPY FOR TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY, et al. A randomized Three-Arm clinical trial (CTPDR Study). Retina Phila Pa. 2022;42:1065\u201376.","journal-title":"Retina Phila Pa"},{"key":"687_CR20","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68:2143\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"687_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","volume":"125","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, et al. Loss to Follow-Up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal Anti-VEGF injections. Ophthalmology. 2018;125:1386\u201392.","journal-title":"Ophthalmology"},{"key":"687_CR22","doi-asserted-by":"crossref","unstructured":"Simmonds M, Llewellyn A, Walker R et al. Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis. Health Technol Assess Winch Engl. 2024:1\u201371.","DOI":"10.3310\/PCGV5709"},{"key":"687_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.oret.2024.08.004","volume":"9","author":"M-M Macaron","year":"2025","unstructured":"Macaron M-M, Al Sabbakh N, Shami MZ, et al. Anti-VEGF injections vs. Panretinal photocoagulation laser therapy for proliferative diabetic retinopathy: A systematic review and Meta-Analysis. Ophthalmol Retina. 2025;9:105\u201321.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00687-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:46:43Z","timestamp":1757209603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00687-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}